Anticorps Monoclonal anti-Beclin 1

Beclin 1 Monoclonal Antibody for WB, IHC, IF-P, Cytometric bead array, Indirect ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF-P, Cytometric bead array, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1C10C4

N° de cat : 66665-1-PBS

Synonymes

BECN1, 1C10C4, ATG 6, ATG6, Beclin1



Informations sur le produit

66665-1-PBS cible Beclin 1 dans les applications de WB, IHC, IF-P, Cytometric bead array, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Mouse / IgG1
Clonalité Monoclonal
Type Anticorps
Immunogène Beclin 1 Protéine recombinante Ag1843
Nom complet beclin 1, autophagy related
Masse moléculaire calculée 52 kDa
Poids moléculaire observé52-60 kDa
Numéro d’acquisition GenBankBC010276
Symbole du gène Beclin 1
Identification du gène (NCBI) 8678
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Beclin 1, also known as ATG6 or VPS30, interacts with various cofactors (e.g. Ambra1, Barkor (Atg14), Rubicon, or UVRAG) to regulate the lipid kinase Vps34 and promote the formation of the BECLIN1-Vps34-Vps15 complex, hence inducing autophagy. Its function (via the BH3 domain) is inhibited by Bcl-2 or Bcl-XL. Beclin 1 (BECN1) is a crucial molecule in the control of the autophagic activity, and its activity is regulated by multiple mechanisms, including the post-translational modification, protein-protein interaction, and subcellular localization. It plays a role in crosstalk between apoptosis and autophagy. It has been reported that Beclin 1 can be cleaved into fragments of 50, 37 and 35 kDa during apoptosis. It is involved in many disorders, including neurodegeneration and cancer (tumorigenesis). Beclin 1 is a mammalian tumor suppressor, and its gene is monoallelically deleted in 75% of ovarian, 50% of breast, and 40% of prostate cancers. Decreased expression of Beclin 1 has also been observed in human brain and lung tumors. The level of Beclin 1 was decreased in the affected brain regions of patients with Alzheimer's disease early in the disease process. Recent studies have also shown that gain and loss of Beclin 1 function affects the death of heart cells.

{{ptg:RelatedPrimaryAntibodies}}